Cough is a sudden expulsion of air through breathing passage that helps to clear mucous or fluids, foreign particles, and microbes. It is a protective reflex action and can be repetitive. Frequent coughing indicates presence of any irritation or disease. Choking, smoking, air pollution, asthama, bacterial infection, chronic bronchitis, lung tumors, and others can be the causes of cough. Cough can be divided into acute cough and chronic cough. Cough suppressants inhibit coughing and irritation in throat. Dextromethorphan, salbutamol, inhaled corticosteroids, and benzonatate are the some drugs which can be used as cough suppressants.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the cough suppressant drugs market.

Top Impacting Factors

• Increase in prevalence of cough all over the globe, surge in adoption of unhealthy lifestyle, rise in consumption of cigarettes, increase in cases of respiratory tract infection, rise in high risk due to exposure to pollens, and surge in geriatric population are the key factors that drive the growth of the market.
• In addition, surge in adoption of highly advance cough suppressant drugs, emerging advance technology in developing countries, R&D activities to improve quality of drugs, launch of novel drugs, rise in infrastructure developments through government funding, and aggressive development strategies by key market players are expected to boost the growth of the market.
• However, side effects related to cough suppressant drugs and stringent regulation for over the counter medicines hinder the growth of the market.
• Contrarily, increase in demand of cost effective treatment and government support for fast track regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Ernest Chemists announced launch of new herbal cough remedy named as Honeykof. This product use in treatment of throat infection and reduce amount of cough.

In 2018, Perrigo Company Plc, announced FDA approval for launch of its OTC brand Mucinex DM Maximum Strength. This product use to reduce repetitive cough and break up mucus.

Key Benefits of the Report

• This study presents the analytical depiction of cough suppressant drugs market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
• The current market is quantitatively analyzed to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Cough Suppressant Drugs Market Report     

• Which are the leading players active in the cough suppressant drugs market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is "cough suppressant drugs"?
• What is "cough suppressant drugs" market prediction in the future?
• Who are the leading global players in the "cough suppressant" market?
• What are the current trends and predicted trends?
• What are the key benefits of the "cough suppressant drugs" market report?

 Key Market Segments

• By Indication
  • Dry Cough
  • Wet Cough
• By Drug Type
  • Dextromethorphan
  • Codeine
  • Noscapine
  • Butamirate
  • Benzonatate
  • Pholcodine
  • Others
• By Dosage Form
  • Syrup
  • Tablet
  • Others
• By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

 
Key Market Players

• GlaxoSmithKline plc.
• Pfizer Inc.
• Aytu BioScience, Inc.
• Mayne Pharma Inc.
• Amneal Pharmaceuticals LLC
• Acella Pharmaceuticals LLC
• Aurobindo Pharma Ltd
• Perrigo Company plc
• Vernalis plc,
• Taro Pharmaceutical Industries Ltd.

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: COUGH SUPPRESSANT DRUGS MARKET, BY INDICATION

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Indication

  • 4.2. Dry Cough

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. Wet Cough

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

• CHAPTER 5: COUGH SUPPRESSANT DRUGS MARKET, BY DRUG TYPE

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Drug Type

  • 5.2. Dextromethorphan

    • 5.2.1. Key Market Trends, Growth Factors and Opportunities

    • 5.2.2. Market Size and Forecast, By Region

    • 5.2.3. Market Share Analysis, By Country

  • 5.3. Codeine

    • 5.3.1. Key Market Trends, Growth Factors and Opportunities

    • 5.3.2. Market Size and Forecast, By Region

    • 5.3.3. Market Share Analysis, By Country

  • 5.4. Noscapine

    • 5.4.1. Key Market Trends, Growth Factors and Opportunities

    • 5.4.2. Market Size and Forecast, By Region

    • 5.4.3. Market Share Analysis, By Country

  • 5.5. Butamirate

    • 5.5.1. Key Market Trends, Growth Factors and Opportunities

    • 5.5.2. Market Size and Forecast, By Region

    • 5.5.3. Market Share Analysis, By Country

  • 5.6. Benzonatate

    • 5.6.1. Key Market Trends, Growth Factors and Opportunities

    • 5.6.2. Market Size and Forecast, By Region

    • 5.6.3. Market Share Analysis, By Country

  • 5.7. Pholcodine

    • 5.7.1. Key Market Trends, Growth Factors and Opportunities

    • 5.7.2. Market Size and Forecast, By Region

    • 5.7.3. Market Share Analysis, By Country

  • 5.8. Others

    • 5.8.1. Key Market Trends, Growth Factors and Opportunities

    • 5.8.2. Market Size and Forecast, By Region

    • 5.8.3. Market Share Analysis, By Country

• CHAPTER 6: COUGH SUPPRESSANT DRUGS MARKET, BY DOSAGE FORM

  • 6.1. Market Overview

    • 6.1.1 Market Size and Forecast, By Dosage Form

  • 6.2. Syrup

    • 6.2.1. Key Market Trends, Growth Factors and Opportunities

    • 6.2.2. Market Size and Forecast, By Region

    • 6.2.3. Market Share Analysis, By Country

  • 6.3. Tablet

    • 6.3.1. Key Market Trends, Growth Factors and Opportunities

    • 6.3.2. Market Size and Forecast, By Region

    • 6.3.3. Market Share Analysis, By Country

  • 6.4. Others

    • 6.4.1. Key Market Trends, Growth Factors and Opportunities

    • 6.4.2. Market Size and Forecast, By Region

    • 6.4.3. Market Share Analysis, By Country

• CHAPTER 7: COUGH SUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview

    • 7.1.1 Market Size and Forecast, By Distribution Channel

  • 7.2. Hospitals Pharmacy

    • 7.2.1. Key Market Trends, Growth Factors and Opportunities

    • 7.2.2. Market Size and Forecast, By Region

    • 7.2.3. Market Share Analysis, By Country

  • 7.3. Retail Pharmacy

    • 7.3.1. Key Market Trends, Growth Factors and Opportunities

    • 7.3.2. Market Size and Forecast, By Region

    • 7.3.3. Market Share Analysis, By Country

  • 7.4. Online Pharmacy

    • 7.4.1. Key Market Trends, Growth Factors and Opportunities

    • 7.4.2. Market Size and Forecast, By Region

    • 7.4.3. Market Share Analysis, By Country

• CHAPTER 8: COUGH SUPPRESSANT DRUGS MARKET, BY REGION

  • 8.1. Market Overview

    • 8.1.1 Market Size and Forecast, By Region

  • 8.2. North America

    • 8.2.1. Key Market Trends and Opportunities

    • 8.2.2. Market Size and Forecast, By Indication

    • 8.2.3. Market Size and Forecast, By Drug Type

    • 8.2.4. Market Size and Forecast, By Dosage Form

    • 8.2.5. Market Size and Forecast, By Distribution Channel

    • 8.2.6. Market Size and Forecast, By Country

    • 8.2.7. U.S. Cough Suppressant Drugs Market

      • 8.2.7.1. Market Size and Forecast, By Indication

      • 8.2.7.2. Market Size and Forecast, By Drug Type

      • 8.2.7.3. Market Size and Forecast, By Dosage Form

      • 8.2.7.4. Market Size and Forecast, By Distribution Channel

    • 8.2.8. Canada Cough Suppressant Drugs Market

      • 8.2.8.1. Market Size and Forecast, By Indication

      • 8.2.8.2. Market Size and Forecast, By Drug Type

      • 8.2.8.3. Market Size and Forecast, By Dosage Form

      • 8.2.8.4. Market Size and Forecast, By Distribution Channel

    • 8.2.9. Mexico Cough Suppressant Drugs Market

      • 8.2.9.1. Market Size and Forecast, By Indication

      • 8.2.9.2. Market Size and Forecast, By Drug Type

      • 8.2.9.3. Market Size and Forecast, By Dosage Form

      • 8.2.9.4. Market Size and Forecast, By Distribution Channel

  • 8.3. Europe

    • 8.3.1. Key Market Trends and Opportunities

    • 8.3.2. Market Size and Forecast, By Indication

    • 8.3.3. Market Size and Forecast, By Drug Type

    • 8.3.4. Market Size and Forecast, By Dosage Form

    • 8.3.5. Market Size and Forecast, By Distribution Channel

    • 8.3.6. Market Size and Forecast, By Country

    • 8.3.7. France Cough Suppressant Drugs Market

      • 8.3.7.1. Market Size and Forecast, By Indication

      • 8.3.7.2. Market Size and Forecast, By Drug Type

      • 8.3.7.3. Market Size and Forecast, By Dosage Form

      • 8.3.7.4. Market Size and Forecast, By Distribution Channel

    • 8.3.8. Germany Cough Suppressant Drugs Market

      • 8.3.8.1. Market Size and Forecast, By Indication

      • 8.3.8.2. Market Size and Forecast, By Drug Type

      • 8.3.8.3. Market Size and Forecast, By Dosage Form

      • 8.3.8.4. Market Size and Forecast, By Distribution Channel

    • 8.3.9. Italy Cough Suppressant Drugs Market

      • 8.3.9.1. Market Size and Forecast, By Indication

      • 8.3.9.2. Market Size and Forecast, By Drug Type

      • 8.3.9.3. Market Size and Forecast, By Dosage Form

      • 8.3.9.4. Market Size and Forecast, By Distribution Channel

    • 8.3.10. Spain Cough Suppressant Drugs Market

      • 8.3.10.1. Market Size and Forecast, By Indication

      • 8.3.10.2. Market Size and Forecast, By Drug Type

      • 8.3.10.3. Market Size and Forecast, By Dosage Form

      • 8.3.10.4. Market Size and Forecast, By Distribution Channel

    • 8.3.11. UK Cough Suppressant Drugs Market

      • 8.3.11.1. Market Size and Forecast, By Indication

      • 8.3.11.2. Market Size and Forecast, By Drug Type

      • 8.3.11.3. Market Size and Forecast, By Dosage Form

      • 8.3.11.4. Market Size and Forecast, By Distribution Channel

    • 8.3.12. Russia Cough Suppressant Drugs Market

      • 8.3.12.1. Market Size and Forecast, By Indication

      • 8.3.12.2. Market Size and Forecast, By Drug Type

      • 8.3.12.3. Market Size and Forecast, By Dosage Form

      • 8.3.12.4. Market Size and Forecast, By Distribution Channel

    • 8.3.13. Rest Of Europe Cough Suppressant Drugs Market

      • 8.3.13.1. Market Size and Forecast, By Indication

      • 8.3.13.2. Market Size and Forecast, By Drug Type

      • 8.3.13.3. Market Size and Forecast, By Dosage Form

      • 8.3.13.4. Market Size and Forecast, By Distribution Channel

  • 8.4. Asia-Pacific

    • 8.4.1. Key Market Trends and Opportunities

    • 8.4.2. Market Size and Forecast, By Indication

    • 8.4.3. Market Size and Forecast, By Drug Type

    • 8.4.4. Market Size and Forecast, By Dosage Form

    • 8.4.5. Market Size and Forecast, By Distribution Channel

    • 8.4.6. Market Size and Forecast, By Country

    • 8.4.7. China Cough Suppressant Drugs Market

      • 8.4.7.1. Market Size and Forecast, By Indication

      • 8.4.7.2. Market Size and Forecast, By Drug Type

      • 8.4.7.3. Market Size and Forecast, By Dosage Form

      • 8.4.7.4. Market Size and Forecast, By Distribution Channel

    • 8.4.8. Japan Cough Suppressant Drugs Market

      • 8.4.8.1. Market Size and Forecast, By Indication

      • 8.4.8.2. Market Size and Forecast, By Drug Type

      • 8.4.8.3. Market Size and Forecast, By Dosage Form

      • 8.4.8.4. Market Size and Forecast, By Distribution Channel

    • 8.4.9. India Cough Suppressant Drugs Market

      • 8.4.9.1. Market Size and Forecast, By Indication

      • 8.4.9.2. Market Size and Forecast, By Drug Type

      • 8.4.9.3. Market Size and Forecast, By Dosage Form

      • 8.4.9.4. Market Size and Forecast, By Distribution Channel

    • 8.4.10. South Korea Cough Suppressant Drugs Market

      • 8.4.10.1. Market Size and Forecast, By Indication

      • 8.4.10.2. Market Size and Forecast, By Drug Type

      • 8.4.10.3. Market Size and Forecast, By Dosage Form

      • 8.4.10.4. Market Size and Forecast, By Distribution Channel

    • 8.4.11. Australia Cough Suppressant Drugs Market

      • 8.4.11.1. Market Size and Forecast, By Indication

      • 8.4.11.2. Market Size and Forecast, By Drug Type

      • 8.4.11.3. Market Size and Forecast, By Dosage Form

      • 8.4.11.4. Market Size and Forecast, By Distribution Channel

    • 8.4.12. Thailand Cough Suppressant Drugs Market

      • 8.4.12.1. Market Size and Forecast, By Indication

      • 8.4.12.2. Market Size and Forecast, By Drug Type

      • 8.4.12.3. Market Size and Forecast, By Dosage Form

      • 8.4.12.4. Market Size and Forecast, By Distribution Channel

    • 8.4.13. Malaysia Cough Suppressant Drugs Market

      • 8.4.13.1. Market Size and Forecast, By Indication

      • 8.4.13.2. Market Size and Forecast, By Drug Type

      • 8.4.13.3. Market Size and Forecast, By Dosage Form

      • 8.4.13.4. Market Size and Forecast, By Distribution Channel

    • 8.4.14. Indonesia Cough Suppressant Drugs Market

      • 8.4.14.1. Market Size and Forecast, By Indication

      • 8.4.14.2. Market Size and Forecast, By Drug Type

      • 8.4.14.3. Market Size and Forecast, By Dosage Form

      • 8.4.14.4. Market Size and Forecast, By Distribution Channel

    • 8.4.15. Rest of Asia Pacific Cough Suppressant Drugs Market

      • 8.4.15.1. Market Size and Forecast, By Indication

      • 8.4.15.2. Market Size and Forecast, By Drug Type

      • 8.4.15.3. Market Size and Forecast, By Dosage Form

      • 8.4.15.4. Market Size and Forecast, By Distribution Channel

  • 8.5. LAMEA

    • 8.5.1. Key Market Trends and Opportunities

    • 8.5.2. Market Size and Forecast, By Indication

    • 8.5.3. Market Size and Forecast, By Drug Type

    • 8.5.4. Market Size and Forecast, By Dosage Form

    • 8.5.5. Market Size and Forecast, By Distribution Channel

    • 8.5.6. Market Size and Forecast, By Country

    • 8.5.7. Brazil Cough Suppressant Drugs Market

      • 8.5.7.1. Market Size and Forecast, By Indication

      • 8.5.7.2. Market Size and Forecast, By Drug Type

      • 8.5.7.3. Market Size and Forecast, By Dosage Form

      • 8.5.7.4. Market Size and Forecast, By Distribution Channel

    • 8.5.8. South Africa Cough Suppressant Drugs Market

      • 8.5.8.1. Market Size and Forecast, By Indication

      • 8.5.8.2. Market Size and Forecast, By Drug Type

      • 8.5.8.3. Market Size and Forecast, By Dosage Form

      • 8.5.8.4. Market Size and Forecast, By Distribution Channel

    • 8.5.9. Saudi Arabia Cough Suppressant Drugs Market

      • 8.5.9.1. Market Size and Forecast, By Indication

      • 8.5.9.2. Market Size and Forecast, By Drug Type

      • 8.5.9.3. Market Size and Forecast, By Dosage Form

      • 8.5.9.4. Market Size and Forecast, By Distribution Channel

    • 8.5.10. UAE Cough Suppressant Drugs Market

      • 8.5.10.1. Market Size and Forecast, By Indication

      • 8.5.10.2. Market Size and Forecast, By Drug Type

      • 8.5.10.3. Market Size and Forecast, By Dosage Form

      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

    • 8.5.11. Argentina Cough Suppressant Drugs Market

      • 8.5.11.1. Market Size and Forecast, By Indication

      • 8.5.11.2. Market Size and Forecast, By Drug Type

      • 8.5.11.3. Market Size and Forecast, By Dosage Form

      • 8.5.11.4. Market Size and Forecast, By Distribution Channel

    • 8.5.12. Rest of LAMEA Cough Suppressant Drugs Market

      • 8.5.12.1. Market Size and Forecast, By Indication

      • 8.5.12.2. Market Size and Forecast, By Drug Type

      • 8.5.12.3. Market Size and Forecast, By Dosage Form

      • 8.5.12.4. Market Size and Forecast, By Distribution Channel

• CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction

  • 9.2. Top Winning Strategies

  • 9.3. Product Mapping Of Top 10 Player

  • 9.4. Competitive Dashboard

  • 9.5. Competitive Heatmap

  • 9.6. Top Player Positioning, 2024

• CHAPTER 10: COMPANY PROFILES

  • 10.1. Pfizer Inc.

    • 10.1.1. Company Overview

    • 10.1.2. Key Executives

    • 10.1.3. Company Snapshot

    • 10.1.4. Operating Business Segments

    • 10.1.5. Product Portfolio

    • 10.1.6. Business Performance

    • 10.1.7. Key Strategic Moves and Developments

  • 10.2. Aytu BioScience, Inc.

    • 10.2.1. Company Overview

    • 10.2.2. Key Executives

    • 10.2.3. Company Snapshot

    • 10.2.4. Operating Business Segments

    • 10.2.5. Product Portfolio

    • 10.2.6. Business Performance

    • 10.2.7. Key Strategic Moves and Developments

  • 10.3. Acella Pharmaceuticals LLC

    • 10.3.1. Company Overview

    • 10.3.2. Key Executives

    • 10.3.3. Company Snapshot

    • 10.3.4. Operating Business Segments

    • 10.3.5. Product Portfolio

    • 10.3.6. Business Performance

    • 10.3.7. Key Strategic Moves and Developments

  • 10.4. Mayne Pharma Inc.

    • 10.4.1. Company Overview

    • 10.4.2. Key Executives

    • 10.4.3. Company Snapshot

    • 10.4.4. Operating Business Segments

    • 10.4.5. Product Portfolio

    • 10.4.6. Business Performance

    • 10.4.7. Key Strategic Moves and Developments

  • 10.5. Taro Pharmaceutical Industries Ltd.

    • 10.5.1. Company Overview

    • 10.5.2. Key Executives

    • 10.5.3. Company Snapshot

    • 10.5.4. Operating Business Segments

    • 10.5.5. Product Portfolio

    • 10.5.6. Business Performance

    • 10.5.7. Key Strategic Moves and Developments

  • 10.6. Amneal Pharmaceuticals LLC

    • 10.6.1. Company Overview

    • 10.6.2. Key Executives

    • 10.6.3. Company Snapshot

    • 10.6.4. Operating Business Segments

    • 10.6.5. Product Portfolio

    • 10.6.6. Business Performance

    • 10.6.7. Key Strategic Moves and Developments

  • 10.7. Aurobindo Pharma Ltd

    • 10.7.1. Company Overview

    • 10.7.2. Key Executives

    • 10.7.3. Company Snapshot

    • 10.7.4. Operating Business Segments

    • 10.7.5. Product Portfolio

    • 10.7.6. Business Performance

    • 10.7.7. Key Strategic Moves and Developments

  • 10.8. GlaxoSmithKline Plc.

    • 10.8.1. Company Overview

    • 10.8.2. Key Executives

    • 10.8.3. Company Snapshot

    • 10.8.4. Operating Business Segments

    • 10.8.5. Product Portfolio

    • 10.8.6. Business Performance

    • 10.8.7. Key Strategic Moves and Developments

  • 10.9. Perrigo Company Plc

    • 10.9.1. Company Overview

    • 10.9.2. Key Executives

    • 10.9.3. Company Snapshot

    • 10.9.4. Operating Business Segments

    • 10.9.5. Product Portfolio

    • 10.9.6. Business Performance

    • 10.9.7. Key Strategic Moves and Developments

  • 10.10. Vernalis Plc,

    • 10.10.1. Company Overview

    • 10.10.2. Key Executives

    • 10.10.3. Company Snapshot

    • 10.10.4. Operating Business Segments

    • 10.10.5. Product Portfolio

    • 10.10.6. Business Performance

    • 10.10.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR DRY COUGH, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR WET COUGH, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 5. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR DEXTROMETHORPHAN, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR CODEINE, BY REGION, 2025-2033 ($MILLION)
• TABLE 7. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR NOSCAPINE, BY REGION, 2025-2033 ($MILLION)
• TABLE 8. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR BUTAMIRATE, BY REGION, 2025-2033 ($MILLION)
• TABLE 9. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR BENZONATATE, BY REGION, 2025-2033 ($MILLION)
• TABLE 10. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR PHOLCODINE, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
• TABLE 12. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 13. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR SYRUP, BY REGION, 2025-2033 ($MILLION)
• TABLE 14. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR TABLET, BY REGION, 2025-2033 ($MILLION)
• TABLE 15. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
• TABLE 16. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 17. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR HOSPITALS PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 18. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 19. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2025-2033 ($MILLION)
• TABLE 20. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 21. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 22. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 23. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 24. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 25. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 26. U.S. COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 27. U.S. COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 28. U.S. COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 29. U.S. COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 30. CANADA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 31. CANADA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 32. CANADA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 33. CANADA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 34. MEXICO COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 35. MEXICO COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 36. MEXICO COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 37. MEXICO COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 38. EUROPE COUGH SUPPRESSANT DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 39. EUROPE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 40. EUROPE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 41. EUROPE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 42. EUROPE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 43. FRANCE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 44. FRANCE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 45. FRANCE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 46. FRANCE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 47. GERMANY COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 48. GERMANY COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 49. GERMANY COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 50. GERMANY COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 51. ITALY COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 52. ITALY COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 53. ITALY COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 54. ITALY COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 55. SPAIN COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 56. SPAIN COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 57. SPAIN COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 58. SPAIN COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 59. UK COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 60. UK COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 61. UK COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 62. UK COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 63. RUSSIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 64. RUSSIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 65. RUSSIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 66. RUSSIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 67. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 68. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 69. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 70. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 71. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 72. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 73. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 74. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 75. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 76. CHINA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 77. CHINA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 78. CHINA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 79. CHINA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 80. JAPAN COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 81. JAPAN COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 82. JAPAN COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 83. JAPAN COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 84. INDIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 85. INDIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 86. INDIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 87. INDIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 88. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 89. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 90. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 91. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 92. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 93. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 94. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 95. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 96. THAILAND COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 97. THAILAND COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 98. THAILAND COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 99. THAILAND COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 100. MALAYSIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 101. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 102. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 103. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 104. INDONESIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 105. INDONESIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 106. INDONESIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 107. INDONESIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 108. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 109. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 110. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 111. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 112. LAMEA COUGH SUPPRESSANT DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 113. LAMEA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 114. LAMEA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 115. LAMEA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 116. LAMEA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 117. BRAZIL COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 118. BRAZIL COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 119. BRAZIL COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 120. BRAZIL COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 121. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 122. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 123. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 124. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 125. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 126. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 127. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 128. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 129. UAE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 130. UAE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 131. UAE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 132. UAE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 133. ARGENTINA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 134. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 135. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 136. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 137. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
• TABLE 138. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2025-2033 ($MILLION)
• TABLE 139. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 140. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 141. PFIZER INC.: KEY EXECUTIVES
• TABLE 142. PFIZER INC.: COMPANY SNAPSHOT
• TABLE 143. PFIZER INC.: OPERATING SEGMENTS
• TABLE 144. PFIZER INC.: PRODUCT PORTFOLIO
• TABLE 145. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 146. AYTU BIOSCIENCE, INC.: KEY EXECUTIVES
• TABLE 147. AYTU BIOSCIENCE, INC.: COMPANY SNAPSHOT
• TABLE 148. AYTU BIOSCIENCE, INC.: OPERATING SEGMENTS
• TABLE 149. AYTU BIOSCIENCE, INC.: PRODUCT PORTFOLIO
• TABLE 150. AYTU BIOSCIENCE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 151. ACELLA PHARMACEUTICALS LLC: KEY EXECUTIVES
• TABLE 152. ACELLA PHARMACEUTICALS LLC: COMPANY SNAPSHOT
• TABLE 153. ACELLA PHARMACEUTICALS LLC: OPERATING SEGMENTS
• TABLE 154. ACELLA PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
• TABLE 155. ACELLA PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 156. MAYNE PHARMA INC.: KEY EXECUTIVES
• TABLE 157. MAYNE PHARMA INC.: COMPANY SNAPSHOT
• TABLE 158. MAYNE PHARMA INC.: OPERATING SEGMENTS
• TABLE 159. MAYNE PHARMA INC.: PRODUCT PORTFOLIO
• TABLE 160. MAYNE PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 161. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
• TABLE 162. TARO PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
• TABLE 163. TARO PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
• TABLE 164. TARO PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
• TABLE 165. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 166. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
• TABLE 167. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
• TABLE 168. AMNEAL PHARMACEUTICALS LLC: OPERATING SEGMENTS
• TABLE 169. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
• TABLE 170. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 171. AUROBINDO PHARMA LTD: KEY EXECUTIVES
• TABLE 172. AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
• TABLE 173. AUROBINDO PHARMA LTD: OPERATING SEGMENTS
• TABLE 174. AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
• TABLE 175. AUROBINDO PHARMA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 176. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
• TABLE 177. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
• TABLE 178. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
• TABLE 179. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
• TABLE 180. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 181. PERRIGO COMPANY PLC: KEY EXECUTIVES
• TABLE 182. PERRIGO COMPANY PLC: COMPANY SNAPSHOT
• TABLE 183. PERRIGO COMPANY PLC: OPERATING SEGMENTS
• TABLE 184. PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
• TABLE 185. PERRIGO COMPANY PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 186. VERNALIS PLC,: KEY EXECUTIVES
• TABLE 187. VERNALIS PLC,: COMPANY SNAPSHOT
• TABLE 188. VERNALIS PLC,: OPERATING SEGMENTS
• TABLE 189. VERNALIS PLC,: PRODUCT PORTFOLIO
• TABLE 190. VERNALIS PLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION
• FIGURE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET
• FIGURE 3. SEGMENTATION COUGH SUPPRESSANT DRUGS MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN COUGH SUPPRESSANT DRUGS MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOUGH SUPPRESSANT DRUGS MARKET
• FIGURE 11. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY INDICATION
• FIGURE 12. COUGH SUPPRESSANT DRUGS MARKET FOR DRY COUGH, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. COUGH SUPPRESSANT DRUGS MARKET FOR WET COUGH, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DRUG TYPE
• FIGURE 15. COUGH SUPPRESSANT DRUGS MARKET FOR DEXTROMETHORPHAN, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 16. COUGH SUPPRESSANT DRUGS MARKET FOR CODEINE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 17. COUGH SUPPRESSANT DRUGS MARKET FOR NOSCAPINE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 18. COUGH SUPPRESSANT DRUGS MARKET FOR BUTAMIRATE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 19. COUGH SUPPRESSANT DRUGS MARKET FOR BENZONATATE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 20. COUGH SUPPRESSANT DRUGS MARKET FOR PHOLCODINE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 21. COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 22. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DOSAGE FORM
• FIGURE 23. COUGH SUPPRESSANT DRUGS MARKET FOR SYRUP, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 24. COUGH SUPPRESSANT DRUGS MARKET FOR TABLET, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 25. COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 26. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
• FIGURE 27. COUGH SUPPRESSANT DRUGS MARKET FOR HOSPITALS PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 28. COUGH SUPPRESSANT DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 29. COUGH SUPPRESSANT DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 34. COMPETITIVE DASHBOARD
• FIGURE 35. COMPETITIVE HEATMAP: COUGH SUPPRESSANT DRUGS MARKET
• FIGURE 36. TOP PLAYER POSITIONING, 2024
• FIGURE 37. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 38. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 39. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 40. AYTU BIOSCIENCE, INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 41. AYTU BIOSCIENCE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 42. AYTU BIOSCIENCE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 43. ACELLA PHARMACEUTICALS LLC: NET SALES, 2022-2024 ($MILLION)
• FIGURE 44. ACELLA PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 45. ACELLA PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 46. MAYNE PHARMA INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 47. MAYNE PHARMA INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 48. MAYNE PHARMA INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 49. TARO PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 50. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 51. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 52. AMNEAL PHARMACEUTICALS LLC: NET SALES, 2022-2024 ($MILLION)
• FIGURE 53. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 54. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 55. AUROBINDO PHARMA LTD: NET SALES, 2022-2024 ($MILLION)
• FIGURE 56. AUROBINDO PHARMA LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 57. AUROBINDO PHARMA LTD: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 58. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 59. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 60. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 61. PERRIGO COMPANY PLC: NET SALES, 2022-2024 ($MILLION)
• FIGURE 62. PERRIGO COMPANY PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 63. PERRIGO COMPANY PLC: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 64. VERNALIS PLC,: NET SALES, 2022-2024 ($MILLION)
• FIGURE 65. VERNALIS PLC,: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 66. VERNALIS PLC,: REVENUE SHARE, BY REGION, 2024 (%)